Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Receivables (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Receivables for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 4152.78% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 4152.78% increase, with the full-year FY2025 number at $11948.0, changed N/A from a year prior.
  • Receivables was $1.6 million for Q4 2025 at Neuphoria Therapeutics, up from $3516.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.6 million in Q4 2025 to a low of $3516.0 in Q3 2025.
  • A 4-year average of $235377.4 and a median of $32541.0 in 2024 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 4152.78% in 2025; the steepest drop was 97.0% in 2025.
  • Neuphoria Therapeutics' Receivables stood at $76528.3 in 2022, then crashed by 86.37% to $10429.1 in 2023, then skyrocketed by 260.36% to $37582.0 in 2024, then soared by 4152.78% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Receivables are $1.6 million (Q4 2025), $3516.0 (Q3 2025), and $11948.0 (Q2 2025).